{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:05:19Z","timestamp":1781460319786,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cct.2025.108144","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T15:48:08Z","timestamp":1762703288000},"page":"108144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV"],"prefix":"10.1016","volume":"160","author":[{"given":"Ana Gabriela","family":"Pires dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Abunimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Mothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary I.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiso M.","family":"Sokhela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Sobhie","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.108144_bb0005","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cct.2025.108144_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/v15122435","article-title":"Breaking the silence: regulation of HIV transcription and latency on the road to a cure","volume":"15","author":"Duggan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.cct.2025.108144_bb0015","article-title":"The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review","volume":"9","author":"Debrabander","year":"2023","journal-title":"J. Virus Erad."},{"issue":"2021","key":"10.1016\/j.cct.2025.108144_bb0020","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cct.2025.108144_bb0025","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0000000000002113","article-title":"Clinical trials of antiretroviral treatment interruption in HIV-infected individuals","volume":"33","author":"Lau","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.cct.2025.108144_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/infdis\/jiac032","article-title":"Balancing statistical power and risk in HIV cure clinical trial design","volume":"226","author":"Lau","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.cct.2025.108144_bb0040","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/cid\/ciz417","article-title":"Systematic review and meta-analysis of treatment interruptions in human immunodeficiency virus (HIV) type 1-infected patients receiving antiretroviral therapy: implications for future HIV cure trials","volume":"70","author":"Stecher","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0050","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/03007995.2022.2088714","article-title":"Comorbidity and comedication burden among people living with HIV in the United States","volume":"38","author":"Paudel","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.cct.2025.108144_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.cct.2025.108144_bb0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10461-015-1164-1","article-title":"The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature","volume":"20","author":"Sweeney","year":"2016","journal-title":"AIDS Behav."},{"key":"10.1016\/j.cct.2025.108144_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2023.0178","article-title":"A systematic review of the impact of HIV-related stigma and serostatus disclosure on retention in care and antiretroviral therapy adherence among women with HIV in the United States\/Canada","volume":"38","author":"Nawfal","year":"2024","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.cct.2025.108144_bb0070","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiz173","article-title":"Risk to nonparticipants in HIV remission studies with treatment interruption: a symposium","volume":"220","author":"Eyal","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0075","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2169\/internalmedicine.9661-22","article-title":"Clinical characteristics of retroviral rebound syndrome: a case report and literature review","volume":"62","author":"Akagi","year":"2023","journal-title":"Intern. Med."},{"key":"10.1016\/j.cct.2025.108144_bb0080","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1172\/JCI136886","article-title":"The immune response fails to control HIV early in initial virus spread","volume":"130","author":"Cohn","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2025.108144_bb0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S2055-6640(20)30287-9","article-title":"Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations","volume":"3","author":"Garner","year":"2017","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.cct.2025.108144_bb0090","unstructured":"T. Ng, G.K. Sahu, D.E. Kennedy, T. Dekhtyar, R. Miller, L. Lu, D. Maji, S. Sousa, K. Taylor, S. Bose, J.F. Cohen-Solal, A. Hernandez Jr, V.A. Pitney, M.J. Patterson, J. Salfeld, ABBV-382, an Anti-\u03b14\u03b27 Ab that enhances HIV-1 antigen presentation for immune-mediated viral control, presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2024, 2024; Denver, CO."},{"key":"10.1016\/j.cct.2025.108144_bb0095","unstructured":"M. Ramgopal, J. Lalezari, A.G. Pires dos Santos, P. Krishnan, T. Vaidya, F. Zhou, N.M. Mostafa, T. Geib, H. Betman, P. Dorr, M.L. Alcaide, Routy, safety, pharmacokinetics, and exploratory efficacy of the PD-1 inhibitor budigalimab in antiretroviral treatment-suppressed people living with HIV-1: Preliminary analysis of 2 phase 1b studies including an analytical treatment interruption, Presented at: European AIDS Clinical Society; October 20, 2023; Warsaw, Poland."},{"key":"10.1016\/j.cct.2025.108144_bb0100","unstructured":"P. Krishnan, A.G. Pires Dos Santos, H. Sharthiya, R.L. Tripathi, T.J. Reisch, T. Vaidya, F. Zhou, M. Ramgopal, M. Oliva, A. Vasanthakumar, D.E. Cohen, J.-P. Routy, P.K. Dorr, Biomarker signatures in phase Ib study with PD-1 inhibitor, budigalimab, in PLWH Undergoing ATI, Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2024, 2024; Denver, CO."},{"key":"10.1016\/j.cct.2025.108144_bb0105","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00262-021-02973-w","article-title":"First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma","volume":"71","author":"Italiano","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cct.2025.108144_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/25787489.2023.2267825","article-title":"Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States","volume":"24","author":"Bilger","year":"2023","journal-title":"HIV Research and Clinical Practice"},{"key":"10.1016\/j.cct.2025.108144_bb0115","author":"Villa"},{"key":"10.1016\/j.cct.2025.108144_bb0120","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S1473-3099(23)00267-0","article-title":"A partner protection package for HIV cure-related trials involving analytical treatment interruptions","volume":"23","author":"Dub\u00e9","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2055-6640(20)30009-1","article-title":"A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption","volume":"6","author":"Peluso","year":"2020","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.cct.2025.108144_bb0130","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.cct.2025.108144_bb0135","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2055-6640(20)30028-5","article-title":"From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: a study participant testimonial","volume":"5","author":"Freshwater","year":"2019","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.cct.2025.108144_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/25787489.2024.2312318","article-title":"Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States","volume":"25","author":"Dub\u00e9","year":"2024","journal-title":"HIV Research and Clinical Practice"},{"key":"10.1016\/j.cct.2025.108144_bb0145","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/aid.2022.0040","article-title":"\"I know that I was a part of making a difference\": participant motivations for joining a cure-directed HIV trial with an analytical treatment interruption","volume":"39","author":"Neergaard","year":"2023","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.cct.2025.108144_bb0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/medethics-2017-104433","article-title":"Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk\/benefit assessment","volume":"44","author":"Henderson","year":"2018","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.cct.2025.108144_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149414","article-title":"How elite controllers and posttreatment controllers inform our search for an HIV-1 cure","volume":"131","author":"Li","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cct.2025.108144_bb0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218960120","article-title":"HIV post-treatment controllers have distinct immunological and virological features","volume":"120","author":"Etemad","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cct.2025.108144_bb0165","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cct.2025.108144_bb0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41467-025-56116-1","article-title":"Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies","volume":"16","author":"Gunst","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cct.2025.108144_bb0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1089\/aid.2019.0118","article-title":"Perspectives on analytical treatment interruptions in people living with HIV and their health care providers in the landscape of HIV cure-focused studies","volume":"36","author":"Lau","year":"2020","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.cct.2025.108144_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2021.0023","article-title":"Considerations for increasing racial, ethnic, gender, and sexual diversity in HIV cure-related research with analytical treatment interruptions: a qualitative inquiry","volume":"38","author":"Dub\u00e9","year":"2022","journal-title":"AIDS Res. Hum. Retrovir."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:44:09Z","timestamp":1781459049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425003386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S1551714425003386"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108144","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108144"}}